UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C

Head & neck, 2009-11, Vol.31 (11), p.1393-1422

2009

Volltextzugriff (PDF)

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

The lancet oncology, 2015-04, Vol.16 (4), p.395-405

2015

Volltextzugriff (PDF)

A population‐based study of therapy and survival for patients with head and neck cancer treated in the community

Cancer, 2012-09, Vol.118 (18), p.4452-4461

2012

Volltextzugriff (PDF)

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

Investigational new drugs, 2019-08, Vol.37 (4), p.666-673

2019

Volltextzugriff (PDF)

Targeting embryonic signaling pathways in cancer therapy

Expert opinion on therapeutic targets, 2012-01, Vol.16 (1), p.131-145

2012

Volltextzugriff (PDF)

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S261-S262

2017

Volltextzugriff (PDF)

A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5616-TPS5616

2023

Volltextzugriff (PDF)

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.274-287

2020

Volltextzugriff (PDF)

Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3014-3014

2020

Volltextzugriff (PDF)

Cancer Stem Cells and Targeting Embryonic Signaling Pathways

Journal of thoracic oncology, 2010-12, Vol.5 (12), p.S492-S494

Ullmann, Claudio Dansky

2010

Volltextzugriff (PDF)

Abstract CT159: A phase 1 study of intraperitoneal MCY-M11 therapy for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT159-CT159

2019

Volltextzugriff (PDF)

Flavopiridol-related Proinflammatory Syndrome Is Associated with Induction of Interleukin-6

Clinical cancer research, 2003-02, Vol.9 (2), p.562-570

2003

Volltextzugriff (PDF)

Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3013-3013

2018

Volltextzugriff (PDF)

IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS3111-TPS3111

2016

Volltextzugriff (PDF)

Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer

Journal of thoracic oncology, 2014-10, Vol.9 (10), p.1443-1448

2014

Volltextzugriff (PDF)

Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival

The cancer journal (Sudbury, Mass.), 2014-03, Vol.20 (2), p.97

2014

Volltextzugriff (PDF)

Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2014-02, Vol.32 (4_suppl), p.217-217

2014

Volltextzugriff (PDF)

Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.605-605

2013

Volltextzugriff (PDF)

Abstract CT122: A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT122-CT122

2023

Volltextzugriff (PDF)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

Drugs in R&D, 2016-03, Vol.16 (1), p.45-52

2016

Volltextzugriff (PDF)

Abstract B070: IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.B070-B070

2016

Volltextzugriff (PDF)

Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors

International journal of clinical pharmacology and therapeutics, 2015-07, Vol.53 (7), p.563

2015

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(19)
Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Oncology
(13)
Female
(9)
Aged
(8)
Male
(8)
Middle Aged
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Adult
(6)
Aurora Kinase A - Antagonists & Inhibitors
(5)
Combined Modality Therapy
(5)
Pharmacology. Drug Treatments
(5)
Animals
(4)
Antineoplastic Agents
(4)
Antineoplastic Agents - Administration & Dosage
(4)
Antineoplastic Agents - Therapeutic Use
(4)
Clinical Trials As Topic
(4)
Neoplasms - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

A population‐based study of therapy and survival for patients with head and neck cancer treated in the community

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

Targeting embryonic signaling pathways in cancer therapy

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma

Cancer Stem Cells and Targeting Embryonic Signaling Pathways

Abstract CT159: A phase 1 study of intraperitoneal MCY-M11 therapy for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Flavopiridol-related Proinflammatory Syndrome Is Associated with Induction of Interleukin-6

Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia

Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors

IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors

Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer

Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival

Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC)

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE)

Abstract CT122: A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

Abstract B070: IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors

Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors

Suchergebnisse filtern